Understanding the Role of Soluble Proteins and Exosomes in Non-invasive Urine-based Diagnosis of Preeclampsia

Overview

Journal Sci Rep

Specialty Science

Date 2024 Oct 15

PMID 39406891

Authors

Taewoon Kim

Harshitha Kallubhavi Choodinatha

Kwang Sik Kim

Kyusoon Shin

Hyeon Ji Kim

Jee Yoon Park

Jong Wook Hong

Luke P Lee

Affiliations

Soon will be listed here.

Abstract

Preeclampsia is a hypertensive disorder of pregnancy that can lead to stillbirth and preterm birth if not treated promptly. Currently, the diagnosis of preeclampsia relies on clinical symptoms such as hypertension and proteinuria, along with invasive blood tests. Here, we investigate the role of soluble proteins and exosomes in noninvasive diagnosing preeclampsia non-invasively using maternal urine and urine-derived exosomes. We quantified the levels of particles and the presence of TSG101 and CD63 in urine and urinary exosomes via the biologically intact exosome separation technology (BEST) platform. Then, we obtained higher levels of soluble proteins such as fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) from urine as it was than urinary exosomes. Compared to commercial blood tests, the sensitivity of the sFlt-1/PlGF ratio was found to be 4.0 times higher in urine tests and 1.5 times higher in tests utilizing urine-derived exosomes. Our findings offer promising possibilities for the early and non-invasive identification of high-risk individuals at risk of preeclampsia, allowing for comprehensive preventive management.

References

Engels T, Pape J, Schoofs K, Henrich W, Verlohren S . Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders. Hypertens Pregnancy. 2013; 32(4):459-73. DOI: 10.3109/10641955.2013.827205. View

Phipps E, Thadhani R, Benzing T, Karumanchi S . Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019; 15(5):275-289. PMC: 6472952. DOI: 10.1038/s41581-019-0119-6. View

Boggess K, Lieff S, Murtha A, Moss K, Beck J, Offenbacher S . Maternal periodontal disease is associated with an increased risk for preeclampsia. Obstet Gynecol. 2003; 101(2):227-31. DOI: 10.1016/s0029-7844(02)02314-1. View

Jeong D, Hyun S, Cho I, Lee K, Ahn K, Kim H . The association between maternal pre-pregnancy body mass index and pregnancy outcomes of preeclampsia. Taiwan J Obstet Gynecol. 2022; 61(3):441-446. DOI: 10.1016/j.tjog.2022.03.008. View

Moufarrej M, Vorperian S, Wong R, Campos A, Quaintance C, Sit R . Early prediction of preeclampsia in pregnancy with cell-free RNA. Nature. 2022; 602(7898):689-694. PMC: 8971130. DOI: 10.1038/s41586-022-04410-z. View

Sibai B . Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003; 102(1):181-92. DOI: 10.1016/s0029-7844(03)00475-7. View

Santillan M, Santillan D, Scroggins S, Min J, Sandgren J, Pearson N . Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model. Hypertension. 2014; 64(4):852-9. PMC: 4162750. DOI: 10.1161/HYPERTENSIONAHA.114.03848. View

Redman C, Sargent I . Pre-eclampsia, the placenta and the maternal systemic inflammatory response--a review. Placenta. 2003; 24 Suppl A:S21-7. DOI: 10.1053/plac.2002.0930. View

Zeisler H, Llurba E, Chantraine F, Vatish M, Staff A, Sennstrom M . Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016; 374(1):13-22. DOI: 10.1056/NEJMoa1414838. View

10.

Klein E, Schlembach D, Ramoni A, Langer E, Bahlmann F, Grill S . Influence of the sFlt-1/PlGF Ratio on Clinical Decision-Making in Women with Suspected Preeclampsia. PLoS One. 2016; 11(5):e0156013. PMC: 4887119. DOI: 10.1371/journal.pone.0156013. View

11.

Maynard S, Min J, Merchan J, Lim K, Li J, Mondal S . Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111(5):649-58. PMC: 151901. DOI: 10.1172/JCI17189. View

12.

Nobrega G, Guida J, Novaes J, Solda L, Pietro L, Luz A . Role of biomarkers (sFlt-1/PlGF) in cases of COVID-19 for distinguishing preeclampsia and guiding clinical management. Pregnancy Hypertens. 2022; 31:32-37. PMC: 9719935. DOI: 10.1016/j.preghy.2022.11.008. View

13.

Verlohren S, Brennecke S, Galindo A, Karumanchi S, Mirkovic L, Schlembach D . Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 2021; 27:42-50. DOI: 10.1016/j.preghy.2021.12.003. View

14.

Leanos-Miranda A, Inova Campos-Galicia , Ramirez-Valenzuela K, Chinolla-Arellano Z, Isordia-Salas I . Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia. Hypertension. 2013; 61(5):1118-25. DOI: 10.1161/HYPERTENSIONAHA.111.00754. View

15.

MacDonald T, Walker S, Hannan N, Tong S, Kaituu-Lino T . Clinical tools and biomarkers to predict preeclampsia. EBioMedicine. 2021; 75:103780. PMC: 8718967. DOI: 10.1016/j.ebiom.2021.103780. View

16.

Roh Y, Jee Lee H, Kim J, Kim H, Kim S, Bong K . Precipitation-based colorimetric multiplex immunoassay in hydrogel particles. Lab Chip. 2020; 20(16):2841-2850. DOI: 10.1039/d0lc00325e. View

17.

Matsubara K, Matsubara Y, Uchikura Y, Sugiyama T . Pathophysiology of Preeclampsia: The Role of Exosomes. Int J Mol Sci. 2021; 22(5). PMC: 7961527. DOI: 10.3390/ijms22052572. View

18.

Zou G, Ji Q, Geng Z, Du X, Jiang L, Liu T . miR-31-5p from placental and peripheral blood exosomes is a potential biomarker to diagnose preeclampsia. Hereditas. 2022; 159(1):35. PMC: 9484067. DOI: 10.1186/s41065-022-00250-z. View

19.

Dutta S, Kumar S, Hyett J, Salomon C . Molecular Targets of Aspirin and Prevention of Preeclampsia and Their Potential Association with Circulating Extracellular Vesicles during Pregnancy. Int J Mol Sci. 2019; 20(18). PMC: 6769718. DOI: 10.3390/ijms20184370. View

20.

Chang X, Yao J, He Q, Liu M, Duan T, Wang K . Exosomes From Women With Preeclampsia Induced Vascular Dysfunction by Delivering sFlt (Soluble Fms-Like Tyrosine Kinase)-1 and sEng (Soluble Endoglin) to Endothelial Cells. Hypertension. 2018; 72(6):1381-1390. DOI: 10.1161/HYPERTENSIONAHA.118.11706. View